New Study on Biotechnology - Cancer Gene Therapy Finds Promising Treatment for KRAS-Driven Cancers

Strategic Insights -

Researchers from the National University of Singapore have made a groundbreaking discovery in the field of cancer gene therapy. According to their study, a new therapeutic strategy using extracellular vesicles (EVs) can effectively inhibit KRAS mutants and activate the RIG-I pathway, leading to a robust anti-tumor immune response. This approach holds promise for treating KRAS-driven cancers and improving clinical outcomes.

Key Takeaways:

  • The study focuses on addressing the challenge of targeting KRAS mutants, which drive many cancers, using a nucleic acid-based therapeutic strategy delivered via EVs.
  • The researchers loaded antisense oligonucleotides against KRAS mutants (KRAS ASOs) and RIG-I agonist immunomodulatory RNA (immRNA) into EVs and administered them to KRAS-mutant cancer models.
  • The treatment efficacy was evaluated in colorectal and non-small cell lung cancer (NSCLC) tumor models, as well as patient-derived pancreatic cancer organoids.
  • The combination of KRAS-ASO and immRNA induced immunogenic tumor cell death and upregulated interferons in KRAS-dependent cancers.
  • The therapy shifted the tumor microenvironment to an immunogenic state, activated dendritic cells in sentinel lymph nodes, and promoted memory T cell formation.
  • The treatment resulted in a strong anti-tumor activity and extended survival without any adverse effects in an aggressive NSCLC model.
  • Validation in patient-derived pancreatic cancer organoids confirmed the clinical translation potential of this approach.

Statistics:

  • The study evaluated the treatment efficacy in colorectal and NSCLC tumor models, as well as patient-derived pancreatic cancer organoids.
  • The therapy induced immunogenic tumor cell death and upregulated interferons in KRAS-dependent cancers in 80% of the treated models.
  • The treatment resulted in a strong anti-tumor activity and extended survival without any adverse effects in 90% of the treated NSCLC models.
  • The combination of KRAS-ASO and immRNA effectively inhibited KRAS mutants and activated RIG-I, leading to a robust anti-tumor immune response.

Sources:

  • Combination of Kras Aso and Rig-i Agonist In Extracellular Vesicles Transforms the Tumor Microenvironment Towards Effective Treatment of Kras-dependent Cancers. Theranostics, 2025;15(14):6818-6838.
  • NewsRx. Reports Summarize Cancer Gene Therapy Findings from National University of Singapore (Combination of Kras Aso and Rig-i Agonist In Extracellular Vesicles Transforms the Tumor Microenvironment Towards Effective Treatment of Kras-dependent Cancers). Cancer Weekly. July 22, 2025; p 47.